XDC THE BIOCONJUGATION LEADER

Serial Number 98069926
Registration 7525176
700

Registration Progress

Application Filed
Jul 3, 2023
Under Examination
Feb 6, 2024
Approved for Publication
Dec 12, 2023
Published for Opposition
Dec 12, 2023
Registered
Oct 1, 2024

Trademark Image

XDC THE BIOCONJUGATION LEADER

Basic Information

Serial Number
98069926
Registration Number
7525176
Filing Date
July 3, 2023
Registration Date
October 1, 2024
Published for Opposition
December 12, 2023
Drawing Code
3

Status Summary

Current Status
Active
Status Code
700
Status Date
Oct 1, 2024
Registration
Registered
Classes
040 042

Rights Holder

WuXi XDC Cayman Inc.

03
Address
PO Box 309
Ugland House
Grand Cayman KY1-1104
KY

Ownership History

WuXi XDC Cayman Inc.

Original Applicant
03
Grand Cayman KY

WuXi XDC Cayman Inc.

Owner at Publication
03
Grand Cayman KY

WuXi XDC Cayman Inc.

Original Registrant
03
Grand Cayman KY

Legal Representation

Attorney
Eric Lamb

USPTO Deadlines

Next Deadline
1745 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20241001)
Due Date
October 01, 2030
Grace Period Ends
April 01, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

21 events
Date Code Type Description Documents
Oct 1, 2024 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Oct 1, 2024 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Aug 28, 2024 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Aug 28, 2024 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Jul 7, 2024 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
May 29, 2024 IUAF S USE AMENDMENT FILED Loading...
Jul 6, 2024 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
May 29, 2024 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Feb 6, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Dec 12, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Dec 12, 2023 PUBO A PUBLISHED FOR OPPOSITION Loading...
Nov 22, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Nov 3, 2023 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Nov 3, 2023 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Nov 3, 2023 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Nov 3, 2023 GNEA F EXAMINERS AMENDMENT E-MAILED Loading...
Nov 3, 2023 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Oct 31, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Aug 4, 2023 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Aug 3, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jul 6, 2023 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 040
Custom assembling of materials for others; custom manufacturing of pharmaceuticals; custom manufacturing of drug conjugates; custom production of pharmaceuticals; custom production of biological preparations; custom manufacturing of antibody-drug conjugates; custom manufacturing of chemical reagents; custom manufacturing of pharmaceutical preparations; custom manufacturing of biomedical preparations; custom manufacture of drug conjugates; processing of pharmaceutical preparations; processing or treating of chemical reagents; processing of antibody drugs; custom manufacturing of antibody drugs; processing of biomedical preparations; processing of biotechnology drug
First Use Anywhere: Oct 20, 2023
First Use in Commerce: Oct 20, 2023
Class 042
Development of products for others in the field of pharmaceuticals; pharmaceutical drug development services; research and development of new products in the field of pharmaceuticals; biochemical research and development; custom design and development of chemical reagent antibodies and conjugate antibodies; research and development in the pharmaceutical, biomedicine and biotechnology fields; research and development of antibodies; research and development of conjugated antibodies; biomedical research services; development of pharmaceutical preparations and medicines; research and development of antibody-drug conjugates; research and development of drug conjugates; preclinical research and evaluation of new drugs; consulting services in the field of technology development; research and development of new products for others; scientific research and development
First Use Anywhere: Oct 20, 2023
First Use in Commerce: Oct 20, 2023

Additional Information

Design Mark
The mark consists of the stylized wording "XDC" to the right of an incomplete oval outline that intersects with another incomplete oval outline. The stylized wording "The Bioconjugation Leader" appears below "XDC".
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
040 042

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BIOCONJUGATION"